Aggarwal, Sanjay K.
Kadmon Corporation (United States)
2 papers on CoChatORCID 0009-0009-9156-7910
Most cited papers
- Verified
ROCK2 inhibition with belumosudil (KD025) for the treatment of chronic graft-versus-host disease
Jagasia, M., Lazaryan, A., Bachier, C. R., Salhotra, A., Weisdorf, D. J., Zoghi, B., Essell, J., Green, L., Schueller, O., Patel, J., et al. (2021) · Journal of Clinical Oncology
Hematopoietic Stem Cell TransplantationImmunodeficiency and Autoimmune Disorders
Cited by 198
- Verified
1339P Clinicopathological characteristics and treatment patterns observed in real-world care in patients with advanced non-small cell lung cancer (NSCLC) and KRAS G12C mutations in the Flatiron Health (FH)-Foundation Medicine (FMI) Clinico-Genomic Database (CGDB)
Aggarwal, S., Whipple, S., Hsu, H., Tu, H., Carrigan, G., Wang, X., Ngarmchamnanrith, G., & Chia, V. (2020) · Annals of Oncology
Lung Cancer Treatments and MutationsLung Cancer Diagnosis and Treatment
Cited by 8
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free